NO802748L - Fremgangsmaate ved fremstilling av et kompleks av polyriboinosinsyre-polyribocytidylsyre med poly-l-lysin-hydrobromid - Google Patents
Fremgangsmaate ved fremstilling av et kompleks av polyriboinosinsyre-polyribocytidylsyre med poly-l-lysin-hydrobromidInfo
- Publication number
- NO802748L NO802748L NO802748A NO802748A NO802748L NO 802748 L NO802748 L NO 802748L NO 802748 A NO802748 A NO 802748A NO 802748 A NO802748 A NO 802748A NO 802748 L NO802748 L NO 802748L
- Authority
- NO
- Norway
- Prior art keywords
- poly
- lysine
- hydrobromide
- complex
- acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 title description 7
- 239000002253 acid Substances 0.000 title description 5
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 42
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 42
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 34
- 102000014150 Interferons Human genes 0.000 claims description 20
- 108010050904 Interferons Proteins 0.000 claims description 20
- 229940079322 interferon Drugs 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 102000006382 Ribonucleases Human genes 0.000 description 4
- 108010083644 Ribonucleases Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000242583 Scyphozoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000010512 thermal transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241001272178 Glires Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282342 Martes americana Species 0.000 description 1
- 241000289419 Metatheria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000606 suspected carcinogen Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7600479A | 1979-09-17 | 1979-09-17 | |
| US15629580A | 1980-06-04 | 1980-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO802748L true NO802748L (no) | 1981-03-18 |
Family
ID=26757523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO802748A NO802748L (no) | 1979-09-17 | 1980-09-16 | Fremgangsmaate ved fremstilling av et kompleks av polyriboinosinsyre-polyribocytidylsyre med poly-l-lysin-hydrobromid |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0025766B1 (es) |
| AU (1) | AU533471B2 (es) |
| DE (1) | DE3068533D1 (es) |
| DK (1) | DK391780A (es) |
| ES (1) | ES495104A0 (es) |
| FI (1) | FI802820A (es) |
| GR (1) | GR70047B (es) |
| IL (1) | IL61006A (es) |
| NO (1) | NO802748L (es) |
| NZ (1) | NZ194880A (es) |
| PT (1) | PT71806B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL86863A0 (en) * | 1987-07-03 | 1988-11-30 | Nippon Shinyaku Co Ltd | Nucleic acid derivatives |
| GB2207138B (en) * | 1987-07-03 | 1992-02-05 | Nippon Shinyaku Co Ltd | Preparation of nucleic acid derivatives. |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| US5624912A (en) * | 1991-08-21 | 1997-04-29 | Burcoglu; Arsinur | Method of treating HIV infection and related secondary infections with defibrotide |
| KR100644172B1 (ko) | 1998-05-25 | 2006-11-10 | 니뽄 신야쿠 가부시키가이샤 | 핵산 함유 복합체 제제의 제조 방법 |
| AU2005332599B2 (en) | 2005-06-08 | 2012-02-16 | Yisheng Biopharma (Singapore) Pte. Ltd. | Polyinosinic acid-polycytidylic acid-based adjuvant |
| US20070166800A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR6801650D0 (pt) * | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
| US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
-
1980
- 1980-09-08 NZ NZ194880A patent/NZ194880A/xx unknown
- 1980-09-09 FI FI802820A patent/FI802820A/fi not_active Application Discontinuation
- 1980-09-09 IL IL61006A patent/IL61006A/xx unknown
- 1980-09-12 GR GR62877A patent/GR70047B/el unknown
- 1980-09-15 DE DE8080401315T patent/DE3068533D1/de not_active Expired
- 1980-09-15 PT PT71806A patent/PT71806B/pt unknown
- 1980-09-15 EP EP80401315A patent/EP0025766B1/en not_active Expired
- 1980-09-16 AU AU62434/80A patent/AU533471B2/en not_active Ceased
- 1980-09-16 NO NO802748A patent/NO802748L/no unknown
- 1980-09-16 ES ES495104A patent/ES495104A0/es active Granted
- 1980-09-16 DK DK391780A patent/DK391780A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8203613A1 (es) | 1982-04-16 |
| PT71806B (en) | 1982-03-26 |
| GR70047B (es) | 1982-07-26 |
| AU6243480A (en) | 1981-03-26 |
| FI802820A (fi) | 1981-03-18 |
| DK391780A (da) | 1981-03-18 |
| ES495104A0 (es) | 1982-04-16 |
| DE3068533D1 (en) | 1984-08-16 |
| IL61006A0 (en) | 1980-11-30 |
| EP0025766A2 (en) | 1981-03-25 |
| NZ194880A (en) | 1983-07-15 |
| AU533471B2 (en) | 1983-11-24 |
| EP0025766A3 (en) | 1982-03-31 |
| IL61006A (en) | 1984-01-31 |
| EP0025766B1 (en) | 1984-07-11 |
| PT71806A (en) | 1980-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4130641A (en) | Induction of interferon production by modified nucleic acid complexes | |
| Carter et al. | Structural requirements of the rIn· rCn complex for Induction of human interferon | |
| US4388306A (en) | Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates | |
| CA1300612C (en) | Immunotherapeutic treatment | |
| US3931397A (en) | Biologically active material | |
| US3937821A (en) | Plasma substitute including artificial starch and method for the preparation thereof | |
| Jameson et al. | Bluetongue virus, an exceptionally potent interferon inducer in mice | |
| NO802748L (no) | Fremgangsmaate ved fremstilling av et kompleks av polyriboinosinsyre-polyribocytidylsyre med poly-l-lysin-hydrobromid | |
| CN104434784B (zh) | 聚肌胞注射液药物组合物和制法 | |
| SU933001A3 (ru) | Способ получени синтетической двунитчатой РНК, обладающей интерферониндуцирующей активностью | |
| CN101612404B (zh) | 鸡新城疫和鸡传染性支气管炎二联活疫苗耐热冻干保护剂 | |
| CA1156145A (en) | Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates | |
| Erkek et al. | Gianotti–Crosti Syndrome preceded by oral polio vaccine and followed by Varicella infection | |
| Blevy | [34] Induction of interferon in vivo and in vitro by polynucleotides and derivatives, and preparation of derivatives | |
| KR0128098B1 (ko) | 항hiv제 | |
| US3859435A (en) | Basic derivatives of lysozyme | |
| RU2206337C1 (ru) | Лекарственный препарат для лечения мышечных дистоний и способ его получения | |
| EP0048283B1 (en) | Virus-inhibiting substance and process for preparing the same | |
| Thang et al. | A continuous high molecular weight base‐paired structure is not an absolute requirement for a potential polynucleotide inducer of interferon | |
| McVicar et al. | Observations of cattle, goats and pigs after administration of synthetic interferon inducers and subsequent exposure to foot and mouth disease virus | |
| JPH05112461A (ja) | 抗ウイルス性抽出物 | |
| GB1569046A (en) | Biologically active substance | |
| US5064758A (en) | Method of preparing a mixture of ribonucleotides | |
| RU2165937C2 (ru) | Полирибонуклеотидный дуплекс на основе полирибоаденилата и полирибоуридилата | |
| RU2172632C1 (ru) | Способ получения иммунотропного противовирусного препарата |